Table 3.
Polyunsaturated fatty acids (PUFA) content in the DAG fraction (nmol/g of wet tissue) in the white gastrocnemius muscle in the control (standard diet) and high-fat diet (HFD) groups after two-week cannabidiol (CBD) treatment.
| Fatty Acid | Control | CBD | HFD | HFD + CBD |
|---|---|---|---|---|
| (18:2n6c) | 41.10 ± 6.95 | 35.10 ± 3.93 a | 31.99 ± 7.50 a | 40.55 ± 7.49 b |
| (20:4n6) | 20.73 ± 2.65 | 27.46 ± 4.72 a | 16.61 ± 1.94 a | 47.76 ± 6.92 a,b |
| (18:3n3) | 4.06 ± 0.62 | 3.73 ± 0.48 | 3.36 ± 0.86 a | 3.07 ± 0.31 a |
| (20:5n3) | 1.37 ± 0.38 | 1.06 ± 0.30 | 1.29 ± 0.31 | 1.05 ± 0.19 a |
| (22:6n3) | 3.68 ± 0.53 | 3.77 ± 0.71 | 5.23 ± 0.97 a | 7.66 ± 0.92 a,b |
| n-6 PUFAs | 61.83 ± 9.13 | 62.56 ± 7.47 | 48.59 ± 7.61 a | 90.40 ± 13.61 a,b |
| n-3 PUFAs | 9.12 ± 1.23 | 8.56 ± 1.07 | 10.05 ± 2.22 | 12.07 ± 1.58 a,b |
The data are expressed as mean values ± SD, n = 10 in each group. a p < 0.05 indicates a significant difference: the control group vs. the examined group in the white gastrocnemius muscle; b p < 0.05 indicates a significant difference: HFD vs. HFD + CBD in the white gastrocnemius muscle; 18:2n6c (linoleic acid, LA); 20:4n6 (arachidonic acid, AA); 18:3n3 (α-linolenic acid, ALA); 20:5n3 (eicosapentaenoic acid, EPA); 22:6n3 (docosahexaenoic acid, DHA).